EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial

Michael J Corley iD, Maya Watanabe, Alina P S Pang iD, Varun B Dwaraka, Ryan Smith iD, Wadzanai Samaneka, Sarah Henn iD, Sonal Munsiff iD, Maria Saumoy, Sara McCallum iD, Kathleen V Fitch iD, Sarah M Chu und 12 weitere

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciaf247 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Michael J Corley und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: HIV Infections, Quinolines, Epigenesis, Genetic, Aging. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

People with human immunodeficiency virus (HIV, PWH) exhibit increased cardiovascular disease (CVD) risk and accelerated biological aging. REPRIEVE demonstrated that pitavastatin reduced major adverse cardiovascular events (MACE) in antiretroviral therapy (ART)-treated PWH with low-to-moderate traditional cardiovascular risk. It remains unknown whether statin therapy can modulate epigenetic aging in PWH.

Methods

We assessed epigenetic aging biomarkers using DNA methylation profiles from peripheral blood mononuclear cells (PBMCs) in a subset of 99 randomly selected US REPRIEVE participants (65 pitavastatin, 34 placebo) at baseline and 24 months. The primary outcomes were changes in second- and third-generation epigenetic clocks PCGrimAge (trained on mortality risk) and DunedinPACE (trained on rate of age-related multi-organ decline).

Results

Median chronological age was 57.0 (Q1, Q3: 56, 58) years and 100% of participants demonstrated epigenetic age acceleration, measured by the difference in PCGrimAge and chronological age (median difference 7.08 years [Q1, Q3: 4.69, 9.64]) at entry. Over 24 months, PCGrimAge remained accelerated with no significant differences between treatment arms (P = .89). However, the median pace of aging by the DunedinPACE increased in the placebo arm (0.036, Q1, Q3 [−0.018, 0.10], P = .021) but not in the pitavastatin arm (0.001, Q1, Q3 [−0.031, 0.036], [P = .77]), treatment group difference (P = .049).

Conclusions

In this pilot study of REPRIEVE, epigenetic age acceleration was demonstrated at trial entry. The biological pace of aging increased over 24 months in the placebo group as compared to the statin group. These preliminary findings suggest pitavastatin may prevent an increase in the pace of biological aging in PWH and support further research into statin therapy as a potential intervention to mitigate accelerated aging. Clinical Trials Registration NCT02344290 (date of initial registration: 22 January 2015).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsQuinolinesEpigenesis, GeneticAgingHydroxymethylglutaryl-CoA Reductase InhibitorsHumansMaleMiddle AgedFemalePilot ProjectsBiomarkersDNA MethylationCardiovascular DiseasesAgedLeukocytes, Mononuclear

Stichwörter der Autor:innen

DNA methylationHIVagingepigenetic clockstatin

Substanzen

pitavastatinQuinolinesBiomarkersHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, USA.
  • Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • TruDiagnostic, Lexington, Kentucky, USA.
  • University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
  • Whitman Walker Health, Washington D.C., USA.
  • Division of Infectious Diseases, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.

ORCID-Profile: Michael J Corley, Alina P S Pang, Ryan Smith, Sarah Henn, Sonal Munsiff, Sara McCallum, Kathleen V Fitch, Judith A Aberg, Carlos D Malvestutto, Carl J Fichtenbaum, Judith S Currier, Pamela S Douglas, Kristine M Erlandson, Heather J Ribaudo, Steven K Grinspoon

Förderung

  • NIAID NIH HHS
  • NHLBI NIH HHS
  • NIDDK NIH HHS

Zitieren

APA

Corley, M. J., Watanabe, M., Pang, A. P. S., Dwaraka, V. B., Smith, R., Samaneka, W., Henn, S., Munsiff, S., Saumoy, M., McCallum, S., Fitch, K. V., Chu, S. M., Diggs, M. R., Aberg, J. A., Malvestutto, C. D., Fichtenbaum, C. J., Currier, J. S., Zanni, M. V., Douglas, P. S., …, & Grinspoon, S. K. (2026). Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf247

Vancouver

Corley MJ, Watanabe M, Pang APS, Dwaraka VB, Smith R, Samaneka W, et al. Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf247

BibTeX
@article{Corley2026,
  author = {Corley, Michael J and Watanabe, Maya and Pang, Alina P S and Dwaraka, Varun B and Smith, Ryan and Samaneka, Wadzanai and Henn, Sarah and Munsiff, Sonal and Saumoy, Maria and McCallum, Sara and Fitch, Kathleen V and Chu, Sarah M and Diggs, Marissa R and Aberg, Judith A and Malvestutto, Carlos D and Fichtenbaum, Carl J and Currier, Judith S and Zanni, Markella V and Douglas, Pamela S and Lu, Michael T and Landay, Alan L and Erlandson, Kristine M and Ribaudo, Heather J and Grinspoon, Steven K},
  title = {Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciaf247}
}
Kostenlos starten →